Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT04735978 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Start date: December 29, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single agent and in combination with anti-PD1 therapy and to determine the recommended Phase 2 dose (RP2D) of RP3.

NCT ID: NCT04721223 Recruiting - Clinical trials for Non Small Cell Lung Cancer

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Start date: April 26, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and tolerability of JAB-3068 administered in investigational regimens in adult participants with advanced solid tumors.

NCT ID: NCT04719065 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor

Start date: January 13, 2021
Phase: Phase 1
Study type: Interventional

This is a multicenter, randomized, open-label, phase Ib study to evaluate the safety, efficacy and pharmacokinetic characteristics of Mitoxantrone Hydrochloride Liposome in subjects with advanced solid tumor.

NCT ID: NCT04713891 Recruiting - Colorectal Cancer Clinical Trials

A Study of KF-0210 in Advanced Solid Tumors Patients

Start date: March 9, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this Phase I, Multi-Center, Open-Label Study is to evaluate the safety, tolerability, Pharmacokinetics, Pharmacodynamics and anti-tumor activity of KF-0210 in participants with advanced solid tumors. The study will be conducted in two parts: phase Ia, and phase Ib.

NCT ID: NCT04705818 Recruiting - Clinical trials for Advanced Solid Tumor

Combining Epigenetic And Immune Therapy to Beat Cancer.

CAIRE
Start date: July 23, 2021
Phase: Phase 2
Study type: Interventional

Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.

NCT ID: NCT04691375 Terminated - Breast Cancer Clinical Trials

A Study of PY314 in Subjects With Advanced Solid Tumors

Start date: October 29, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including pembrolizumab, if approved for that indication).

NCT ID: NCT04689100 Recruiting - Clinical trials for Advanced Solid Tumor

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Start date: April 11, 2017
Phase: Phase 1
Study type: Interventional

This study is a Phase I, open label, multi-center study of to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.

NCT ID: NCT04687423 Recruiting - Clinical trials for Advanced Solid Tumor

Study of FCN-011 in Patients With Advanced Solid Tumor(Phase I)and NTRK Fusion Positive Advanced Solid Tumor (Phase II)

Start date: April 13, 2021
Phase: Phase 1
Study type: Interventional

A multicenter, open, single-arm phase I dose exploration and phase II extended study was conducted to evaluate the safety, tolerability, pharmacokinetic characteristics, and primary antitumor activity of FCN-011 in patients with advanced solid tumor (phase I) and NTRK fusion positive advanced solid tumor (phase II)

NCT ID: NCT04682431 Terminated - Breast Cancer Clinical Trials

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Start date: November 10, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).

NCT ID: NCT04675528 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Food Effect on Pharmacokinetics and SafEty of DHP107 (Liporaxel®) FEEL Study

FEEL
Start date: January 2021
Phase: Phase 1
Study type: Interventional

To evaluate the food effect on pharmacokinetics of DHP107 in patients with advanced solid tumors.